Combination of Rapamycin and MK-2206 Induced Cell Death via Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines

Abstract

Neuroblastoma (NB) is the most common pediatric malignant extracranial solid tumor. Despite multi-modality therapies, the emergence of drug resistance is an obstacle in the treatment of high-risk NB patients (with MYCN amplification). In our previous study, we found that rapamycin and MK-2206 synergistically induced cell death in MYCN-amplified cell lines but the mechanisms remained unclear. In our present study, either 3-MA or necroatatin-1 blocked the cell death induced by rapamycin and MK-2206, but z-VAD-fmk did not block this cell death. The expressions of autophagy markers (ATG5, ATG7, Beclin-1, LC3 B) and the necroptosis marker RIPK3 increased and another necroptosis marker RIPK1 decreased after the combination treatment of rapamycin and MK-2206, and were accompanied by the morphological characteristics of autophagy and necroptosis. In NB xenograft tumor tissues, the expressions of autophagy and necroptosis markers were consistent with observations in vitro. These data suggested that autophagy and necroptosis contributed to the cell death induced by rapamycin and MK-2206 in NB cells. To understand the role of MYCN in this process, MYCN expression was downregulated in MYCN-amplified cell lines (NGP, BE2) using siRNAs and was upregulated in MYCN non-amplified cell lines (AS, SY5Y) using plasmid. We found the cell death induced by rapamycin and MK-2206 was MYCN-dependent. We also found that the metabolic activity in NB cells was correlated with the expression level of MYCN. This study delineates the role of MYCN in the cell death induced by combination treatment of rapamycin and MK-2206 in MYCN-amplified NB cells.

LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma

“…Therefore, accelerating autophagic degradation of EGFR may be the potential strategy for overcoming EGFR-TKI resistance in LUAD. In the current study, mTOR inhibitor rapamycin, which can also induce cell death via promoting autophagy [ 40 ], actually did increase icotinib sensitivity in icotinib-resistant LUAD cells. Other mTOR inhibitors, such as torin2 and BIBW2992) [ 8 , 9 ] were also reported to be able to induce apoptosis and inhibit cell proliferation in EGFR-TKI-resistant NSCLC cells by negative feedback regulation of Akt/mTOR signaling and inducing autophagy, suggesting promising therapeutic strategy in NSCLC with EGFR-TKI resistant phenotype.…”

TNF-α-induced protein 8-like 2 negatively regulates the immune function of dendritic cells by suppressing autophagy via the TAK1/JNK pathway in septic mice

“…We applied the autophagy inhibitor 3-MA and the autophagy inducer rapamycin (Rap) to change autophagy status. In the treatment groups, rapamycin (5 mg/kg) [ 29 , 30 ] was given by intraperitoneal injection 1 h after CLP operation, and 3-MA (15 mg/kg) [ 31 ] was intraperitoneally injected 30 min before CLP operation.…”

Molecular Mechanisms of MYCN Dysregulation in Cancers

“…mTOR directly phosphorylates and inactivates eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1), which leads to activation of eIF4E and thus promotes cap-dependent translation of mRNAs including MYC family ( 112 ). Pharmacological inhibition of the AKT/mTOR pathway reduces N-MYC level and exhibits therapeutic efficacy in MYCN -amplified neuroblastoma ( 113 , 114 ).…”